422 results on '"Chambers, Daniel C."'
Search Results
102. Bronchiolitis obliterans syndrome ‘endotypes’ in haematopoietic stem cell transplantation
103. Successful establishment of primary small airway cell cultures in human lung transplantation
104. Diagnosis and management of connective tissue disease‐associated interstitial lung disease in Australia and New Zealand: A position statement from the Thoracic Society of Australia and New Zealand.
105. The Design and Rationale of the Trail1 Trial: A Randomized Double-Blind Phase 2 Clinical Trial of Pirfenidone in Rheumatoid Arthritis-Associated Interstitial Lung Disease.
106. Increasing complexity of thoracic transplantation and the rise of multiorgan transplantation around the world: Insights from the International Society for Heart and Lung Transplantation Registry
107. Transcriptomics and single‐cell RNA‐sequencing
108. Autologous Adoptive T-cell Therapy for Recurrent or Drug-resistant Cytomegalovirus Complications in Solid Organ Transplant Recipients: A Single-arm Open-label Phase I Clinical Trial
109. Diagnosis and management of idiopathic pulmonary fibrosis: Thoracic Society of Australia and New Zealand and Lung Foundation Australia position statements summary
110. The Registry of the International Society for Heart and Lung Transplantation: Thirty-fourth Adult Heart Transplantation Report—2017; Focus Theme: Allograft ischemic time
111. Registry of the International Society for Heart and Lung Transplantation: Twentieth Pediatric Lung and Heart-Lung Transplantation Report—2017; Focus Theme: Allograft ischemic time
112. The Registry of the International Society for Heart and Lung Transplantation: Twentieth Pediatric Heart Transplantation Report—2017; Focus Theme: Allograft ischemic time
113. The Registry of the International Society for Heart and Lung Transplantation: Thirty-fourth Adult Lung And Heart-Lung Transplantation Report—2017; Focus Theme: Allograft ischemic time
114. Mesenchymal Stromal Cell Therapy for Chronic Lung Allograft Dysfunction: Results of a First-in-Man Study
115. Autologous Adoptive T-cell Therapy for Recurrent or Drug-resistant Cytomegalovirus Complications in Solid Organ Transplant Recipients: A Single-arm Open-label Phase I Clinical Trial.
116. Transcriptomics and single‐cell RNA‐sequencing.
117. Nintedanib for idiopathic pulmonary fibrosis: An Asian perspective
118. Low levels of physical activity predict worse survival to lung transplantation and poor early post-operative outcomes
119. Successful treatment of cytomegalovirus associated hemophagocytic lymphohistiocytosis with the interleukin 1 inhibitor – anakinra
120. Erratic tacrolimus exposure, assessed using the standard deviation of trough blood levels, predicts chronic lung allograft dysfunction and survival
121. Diagnosis and management of idiopathic pulmonary fibrosis: Thoracic Society of Australia and New Zealand and Lung Foundation Australia position statements summary.
122. Bronchiolitis obliterans syndrome, hypogammaglobulinemia, and infectious complications of lung transplantation
123. Regional Differences in Susceptibiity of Bronchial Epithelium to Mesenchymal Transition and Inhibition by the Macrolide Antibiotic Azithromycin
124. Increased expression of graft intraepithelial T-Cell pro-inflammatory cytokines compared with native lung during episodes of acute rejection
125. The airway epithelium is a direct source of matrix degrading enzymes in bronchiolitis obliterans syndrome
126. Where Do The Bronchioles Go? Epithelial-Mesenchymal Transition (EMT) Induction And Prevention In Epithelial Cells From Lung Transplant Patients
127. A novel approach to the assessment of lymphocytic bronchiolitis after lung transplantation—transbronchial brush
128. Adverse outcomes of labour in public and private hospitals in Australia
129. Successful establishment of primary small airway cell cultures in human lung transplantation
130. Cells of Epithelial Lineage Are Present in Blood, Engraft the Bronchial Epithelium, and Are Increased in Human Lung Transplantation
131. Are Blood Cultures Necessary in Community-Acquired Pneumonia?
132. Sex- and Race-Based Differences in the Treatment of Interstitial Lung Diseases in North America and Australasia
133. Exchange dynamics of nitric oxide in the human nose
134. The ongoing quest for a fountain of youth: Cell therapy for pulmonary fibrosis.
135. Successful treatment of cytomegalovirus associated hemophagocytic lymphohistiocytosis with the interleukin 1 inhibitor - anakinra.
136. Adverse outcomes of labour in public and private hospitals in Australia.
137. Management of infectious disease syndromes in thoracic organ transplants and mechanical circulatory device recipients: a Delphi panel.
138. Exertional Desaturation During the 6-Minute Walk Test vs Daily Life in People With Fibrotic Interstitial Lung Disease.
139. Treatment of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis: A position statement from the Thoracic Society of Australia and New Zealand 2023 revision.
140. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-sixth adult heart transplantation report — 2019; focus theme: Donor and recipient size match.
141. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Twenty-second pediatric lung and heart-lung transplantation report—2019; Focus theme: Donor and recipient size match.
142. Bronchiolitis obliterans syndrome–free survival after lung transplantation: An International Society for Heart and Lung Transplantation Thoracic Transplant Registry analysis.
143. A Methodological Approach to Identify Natural Compounds with Antifibrotic Activity and the Potential to Treat Pulmonary Fibrosis Using Single-Cell Sequencing and Primary Human Lung Macrophages.
144. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-fifth Adult Heart Transplantation Report—2018; Focus Theme: Multiorgan Transplantation.
145. Basal cell carcinomas in organ transplant recipients versus the general population: clinicopathologic study.
146. Destructive and topical treatments of skin lesions in organ transplant recipients and relation to skin cancer.
147. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: 23rd pediatric heart transplantation report—2020; focus on deceased donor characteristics.
148. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: 37th adult heart transplantation report—2020; focus on deceased donor characteristics.
149. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Twenty-third pediatric lung transplantation report — 2020; focus on deceased donor characteristics.
150. Incidence and outcome of post-transplant lymphoproliferative disorders in lung transplant patients: Analysis of ISHLT Registry.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.